S'abonner

Improving cellular therapy for primary immune deficiency diseases: Recognition, diagnosis, and management - 12/08/11

Doi : 10.1016/j.jaci.2009.10.022 
Linda M. Griffith, MD, PhD a, Morton J. Cowan, MD b, Luigi D. Notarangelo, MD c, Jennifer M. Puck, MD d, Rebecca H. Buckley, MD e, Fabio Candotti, MD f, Mary Ellen Conley, MD g, Thomas A. Fleisher, MD h, H. Bobby Gaspar, MD, PhD i, Donald B. Kohn, MD j, Hans D. Ochs, MD k, Richard J. O’Reilly, MD l, J. Douglas Rizzo, MD, MS m, Chaim M. Roifman, MD, FRCP, FCACB n, Trudy N. Small, MD l, William T. Shearer, MD, PhD o,

workshop participants

  See Appendix E1 in this article’s Online Repository at www.jacionline.org for a list of expert opinion and workshop participants.

a Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md 
b Pediatric Blood and Marrow Transplant Division, UCSF Children’s Hospital, San Francisco, Calif 
c Division of Immunology and the Manton Center for Orphan Disease Research, Children’s Hospital, Harvard Medical School, Boston, Mass 
d Department of Pediatrics, Institute for Human Genetics, University of California San Francisco, San Francisco, Calif 
e Pediatric Allergy and Immunology, Duke University School of Medicine, Durham, NC 
f Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Md 
g Department of Pediatrics, University of Tennessee College of Medicine and Department of Immunology, St Jude Children’s Research Hospital, Memphis, Tenn 
h Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Md 
i Institute of Child Health, Great Ormond Street Hospital, University College London, London, United Kingdom 
j Departments of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Calif 
k Center for Immunology and Immunotherapy, Seattle Children’s Hospital Research Institute, Seattle, Wash 
l Departments of Pediatrics and Immunology, Memorial Sloan Kettering Cancer Center, New York, NY 
m Center for International Blood and Marrow Transplant Research/Medical College of Wisconsin, Milwaukee, Wis 
n Division of Immunology and Allergy, the Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada 
o Pediatric Allergy & Immunology, Texas Children’s Hospital, Baylor College of Medicine, Houston, Tex 

Reprint requests: William T. Shearer, MD, PhD, Department of Allergy & Immunology, Texas Children’s Hospital, Baylor College of Medicine, MC FC330.01, 6621 Fannin St/Ste A-380, Houston TX, 77030-2399.

Abstract

More than 20 North American academic centers account for the majority of hematopoietic stem cell transplantation (HCT) procedures for primary immunodeficiency diseases (PIDs), with smaller numbers performed at additional sites. Given the importance of a timely diagnosis of these rare diseases and the diversity of practice sites, there is a need for guidance as to best practices in management of patients with PIDs before, during, and in follow-up for definitive treatment. In this conference report of immune deficiency experts and HCT physicians who care for patients with PIDs, we present expert guidance for (1) PID diagnoses that are indications for HCT, including severe combined immunodeficiency disease (SCID), combined immunodeficiency disease, and other non-SCID diseases; (2) the critical importance of a high degree of suspicion of the primary care physician and timeliness of diagnosis for PIDs; (3) the need for rapid referral to an immune deficiency expert, center with experience in HCT, or both for patients with PIDs; (4) medical management of a child with suspicion of SCID/combined immunodeficiency disease while confirming the diagnosis, including infectious disease management and workup; (5) the posttransplantation follow-up visit schedule; (6) antimicrobial prophylaxis after transplantation, including gamma globulin administration; and (7) important indications for return to the transplantation center after discharge. Finally, we discuss the role of high-quality databases in treatment of PIDs and HCT as an element of the infrastructure that will be needed for productive multicenter clinical trials in these rare diseases.

Le texte complet de cet article est disponible en PDF.

Key words : Allogeneic hematopoietic stem cell transplantation, gene therapy, primary immunodeficiency, clinical trial

Abbreviations used : ADA, ALC, CGD, CIBMTR, CID, CMV, CT, Cy, GT, GVHD, HCT, HLH, NK, PCP, PE, PID, PIDTC, SCID, TMP/SMX, USIDNET, WAS


Plan


 This workshop was supported by the Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, and the Office of Rare Diseases Research, National Institutes of Health, Bethesda, Md.
 Disclosure of potential conflict of interest: M. J. Cowan has received research support from the National Institutes of Health; has provided expert witness testimony on the topic of transplant-related mortality; and is Chair of PSIG at the American Society for Blood and Marrow Transplantation. L. D. Notarangelo has received research support from the Manton Foundation, and is on the Steering Committee for the United States Immunodeficiency Network. J. Puck has received research support from the National Institutes of Health, Jeffrey Modell Foundation, United States Immunodeficiency Network, and Baxter, Inc. R. H. Buckley has received research support from the National Institutes of Health, and is Chair of the Medical Advisory Committee for the Immune Deficiency Foundation. M. E. Conley is a consultant for Pharmacyclics; has received royalties from Santa Cruz Biotechnology; and has received research support from the National Institutes of Health. H. R. Gaspar has received research support from the Medical Research Council (UK) and the European Union. H. D. Ochs is on advisory boards for Baxter and CSL Behring, and has received research support from the Jeffrey Modell Foundation, Genetic Defects of Immunity (NIH/NIAID), and Flebogamma 5%. T. N. Small is speaker for Pfizer; is on an advisory board for Wyeth; is on the Data and Safety Monitoring Committee for the American Medical Directors Association; and is married to an employee of Pfizer. The other authors declare that they have no relevant conflicts of interest to disclose.
 The opinions expressed are those of the authors and do not represent the position of the National Institute of Allergy and Infectious Diseases, the Office of Rare Diseases Research, the National Institutes of Health, or the US Government.
 Report of a workshop sponsored by the National Institute of Allergy and Infectious Diseases and the Office of Rare Diseases Research, National Institutes of Health, Bethesda, Md, May 21-22, 2009.


© 2009  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 124 - N° 6

P. 1152 - décembre 2009 Retour au numéro
Article précédent Article précédent
  • Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses
| Article suivant Article suivant
  • Primary immunodeficiencies: 2009 update
  • International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies, Luigi D. Notarangelo, Alain Fischer, Raif S. Geha, Jean-Laurent Casanova, Helen Chapel, Mary Ellen Conley, Charlotte Cunningham-Rundles, Amos Etzioni, Lennart Hammartröm, Shigeaki Nonoyama, Hans D. Ochs, Jennifer Puck, Chaim Roifman, Reinhard Seger, Josiah Wedgwood

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.